Living Cell Technologies

Living Cell Technologies

Living Cell Technologies | Home. Learn more

Launch date
Employees
Market cap
€12.5m
Enterprise valuation
€10m (Public information from Sep 2023)
Auckland Auckland (HQ)

Financials

Estimates*

Edit
Revenues, earnings & profits over time
AUD2020202120222023
Revenues<1m---
EBITDA(3.1m)(2.3m)(2.4m)(2.1m)
% EBITDA margin(99304 %)---
Profit(<1m)(1.5m)(2.0m)(2.1m)
% profit margin(30570 %)---
R&D budget2.4m1.6m1.5m1.3m
R&D % of revenue75246 %---
  • Edit
DateInvestorsAmountRound
-

N/A

-
N/A

N/A

IPO
N/A

$5.6m

Post IPO Equity

$754k

Grant

N/A

Grant
Total Funding€685k

Recent News about Living Cell Technologies

Edit
More about Living Cell Technologiesinfo icon
Edit

LCT Global is a biotechnology company focused on discovering, developing, and commercializing regenerative treatments for serious diseases. The company specializes in using naturally occurring cells, such as neonatal porcine choroid plexus cells, encapsulated in alginate to restore function in affected patients. LCT Global operates in the healthcare and biotechnology markets, targeting both clinical and commercial applications. The business model revolves around research and development, clinical trials, and partnerships with other healthcare organizations to bring their innovative therapies to market. Revenue is generated through licensing agreements, partnerships, and eventual sales of approved treatments.

Keywords: regenerative treatments, biotechnology, neonatal porcine cells, alginate capsules, healthcare, clinical trials, partnerships, licensing, commercialization, innovative therapies.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.